Eli Lilly Stock Down 8% as $900B Valuation Concerns
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Eli Lilly's valuation stands at roughly $900 billion, driving sky‑high expectations for its stock price.
- Analysts have a consensus price target of about $1,230 for Eli Lilly, implying a potential 24% upside from current levels.
- The stock has surged more than 400% over the past five years and now trades at over 40× its trailing earnings.
- Eli Lilly plans to launch a GLP‑1 weight‑loss pill this year, adding a new product to its portfolio.
- GLP‑1 treatments Zepbound and Mounjaro are in high demand, generating billions in revenue for the company.
- The stock is down around 8% this year, reflecting short‑term volatility tied to its high valuation.
Why it matters: Investors risk heightened exposure to volatility as the stock’s steep $900 billion valuation leaves little margin of safety, while the company’s future growth hinges on new GLP‑1 products and its ability to fend off rising competition, making short‑term price swings more likely.
Ask SkimNews
